Woulgan® to be listed on UK Drug Tariff

Tromsø (19. October 2017) Biotec Pharmacon’s (OSE:Biotec) wholly owned subsidiary Biotec BetaGlucans has received feedback from the NHS that Woulgan will be listed on the UK Drug Tariff from January 2018

-This is a key milestone for us because it gives Woulgan access to a major European market. It is also a strong signal to other markets because an objective analysis has concluded that Woulgan is not only clinically effective, but also cost effective in the treatment of challenging wounds. We will now focus our efforts on a successful launch in January 2018, says CEO Christian Jørgensen.

The strategy for Woulgan® is to establish a portfolio of advanced wound care products based on the Company’s proprietary beta-glucan technology.

For additional information,

Christian Jørgensen, CEO, +47 477 92 457, Christian.jorgensen@biotec.no

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics, representing growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.